Compare Travere Therapeutics Inc. Common Stock (TVTX) vs WisdomTree Inc. Common Stock (WT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs WisdomTree Inc. Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while WisdomTree Inc. Common Stock trades at $21.02 (market cap $3.27B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and WisdomTree Inc. Common Stock pays a 0.56% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and WisdomTree Inc. Common Stock for 6 Days on average.
| TVTX | WT | |
|---|---|---|
Market Cap | $4.88B | $3.27B |
Volume | 1,668,577 | 2,488,313 |
Sector | Health | Financials |
52-Week High | $67.52 | $25.04 |
52-Week Low | $26.79 | $10.73 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $4.02B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WisdomTree (WT) trades at $21.61, down 2.83% on the day, near the analyst low target of $21.30. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong profitability margins and consistent earnings beats. Recent news highlights WisdomTree's expansion into tokenized funds and new ETF launches, signaling growth initiatives.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings and a $26.05 price target, but risks include high valuation multiples and negative investing cash flow trends. Earnings momentum from recent beats supports upside potential, though investors face volatility from market sentiment and execution risks in new business lines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About WisdomTree Inc. Common Stock
WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →
